Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pfizer europe ma eeig - neisseria meningitidis c gr. (padermė c11) polisacharidas (de-o-acetilas) - injekcinė suspensija užpildytame švirkšte - 10 µg/0,5 ml - meningococcal vaccines

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pfizer europe ma eeig - metilprednizolonas - milteliai ir tirpiklis injekciniam tirpalui - 1000 mg; 500 mg; 250 mg; 40 mg; 1 g - methylprednisolone

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pfizer europe ma eeig - idarubicinas - milteliai injekciniam tirpalui - 5 mg; 10 mg - idarubicin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pfizer europe ma eeig - linezolidas - granulės geriamajai suspensijai - 100 mg/5 ml; 600 mg; 2 mg/ml - linezolid

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pfizer europe ma eeig - amlodipinas/atorvastatinas - plėvele dengtos tabletės - 5 mg/10 mg; 10 mg/10 mg - atorvastatin and amlodipine

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pfizer europe ma eeig - celekoksibas - kietosios kapsulės - 100 mg; 200 mg - celecoxib

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

pfizer italia s.r.l. - kabergolinas - tabletės - 500 µg - cabergoline

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer limited - tofacitinib - artritas, reumatas - imunosupresantai - reumatoidinio artrito gydymas.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer europe ma eeig  - tanezumab - osteoarthritis; pain - analgetikai - treatment of moderate to severe chronic pain associated with osteoarthritis (oa) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (nsaids) and/or any opioid is ineffective, not tolerated or inappropriate.